The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Open accessAbstract
Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite tremendous advances in understanding the genetic basis of MDS and AML, cure rates have not substantially improved in the last 40 years (45).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citationMyelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Self-citationBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431
Self-citationSanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Self-citationBERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322
Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citationAul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
Self-citationPrognostic implications of morphology and karyotype in primary myelodysplastic syndromes
Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246
Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232
Cited by
Sorted by citations
Items 901–1,000 of 1,003
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia
Breccia, M., & Alimena, G. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.522570 · Cited by 50
Bacher, U., Haferlach, T., Schnittger, S., Zenger, M., Meggendorfer, M., Jeromin, S., Roller, A., Großmann, V., Krauth, M., Alpermann, T., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12710 · Cited by 50
The classification of MDS: From FAB to WHO and beyond
Vardiman, J. W. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.08.008 · Cited by 51
Lima, M. J. G. D., Champlin, R. E., Thall, P. F., Wang, X., Martin, T. G., Cook, J. D., McCormick, G., Qazilbash, M. H., Kebriaei, P., Couriel, D. R., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405014 · Cited by 50
Fei, C., Zhao, Y., Guo, J., Gu, S., Li, X., & Chang, C. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12385 · Cited by 51
Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes
Li, X. O., Xu, F., Chang, C., Byon, J. C. H., Papayannopoulou, T., Deeg, H. J., & Marcondes, A. M. (2012) · Haematologica · doi:10.3324/haematol.2012.071753 · Cited by 50
Corsetti, M. T., Salvi, F., Perticone, S., Baraldi, A., Paoli, L. D., Gatto, S., Pietrasanta, D., Pini, M., Primon, V., Zallio, F., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.02.021 · Cited by 49
Badawi, M. A., Vickars, L. M., Chase, J. M., & Leitch, H. A. (2010) · Advances in Hematology · doi:10.1155/2010/164045 · Cited by 52
Festuccia, M. B., Deeg, H. J., Gooley, T. A., Baker, K., Wood, B. L., Fang, M., Sandmaier, B. M., & Scott, B. L. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.03.029 · Cited by 50
The clonal origins of leukemic progression of myelodysplasia
Kim, T., Tyndel, M. S., Kim, H., Ahn, J.-S., Choi, S. H., Park, H., Kim, Y.-K., Yang, D.-H., Lee, J.-J., Jung, S.-H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.17 · Cited by 49
Carvalho, G., Fabre, C., Braun, T., Grosjean, J., Adès, L., Agou, F., Tasdemir, E., Boehrer, S., Israël, A., Véron, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210043 · Cited by 50
Self-citationWu, F., Oka, Y., Tsuboi, A., Elisseeva, O. A., Ogata, K., Nakajima, H., Fujiki, F., Masuda, T., Murakami, M., Yoshihara, S., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403539 · Cited by 50
Wu, L., Song, L., Xu, L. P., Chang, C., Xu, F., Wu, D., He, Q., Su, J., Zhou, L., Xiao, C., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4305-2 · Cited by 50
Mo, X.-D., Xu, L.-P., Zhang, X.-H., Liu, D.-H., Wang, Y., Chen, H., Yan, C.-H., Chen, Y.-H., Han, W., Wang, F.-R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.223 · Cited by 49
Pellagatti, A., Benner, A., Mills, K., Cazzola, M., Giagounidis, A. A. N., Perry, J., Malcovati, L., Porta, M. G. D., Jädersten, M., Verma, A. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5626 · Cited by 47
Supportive Care and Use of Hematopoietic Growth Factors in Myelodysplastic Syndromes
Hellström‐Lindberg, E., & Malcovati, L. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.10.004 · Cited by 49
Myelodysplasia Cutis Versus Leukemia Cutis
Osio, A., Battistella, M., Feugeas, J., Cuccuini, W., Noguera, M., Petrella, T., Raffoux, E., Janin, A., & Pennamen, M. V. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.146 · Cited by 49
Ximeri, M., Galanopoulos, A. G., Klaus, M., Parcharidou, A., Giannikou, K., Psyllaki, M., Symeonidis, A. S., Pappa, V., Kartasis, Z., Liapi, D., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010876 · Cited by 50
Wang, S. A., Galili, N., Černý, J., Sechman, E. V., Chen, S. S., Loew, J. M., Liu, Q., Fadare, O., Hasserjian, R. P., Jones, D. M., et al. (2006) · American Journal of Clinical Pathology · doi:10.1309/fu04-p779-u310-r3ee · Cited by 49
Zeidan, A. M., Stahl, M. F., Sekeres, M. A., Steensma, D. P., Komrokji, R. S., & Gore, S. D. (2017) · Cancer · doi:10.1002/cncr.30903 · Cited by 49
Ku, Y., Park, J., Cho, R., Lee, Y.-K., Park, H.-M., Kim, M. A., Hur, K., Byun, S. Y., Liu, J., Lee, Y.-S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016289118 · Cited by 49
Yee, K. W. L., Cortes, J. E., Ferrajoli, A., Garcia‐Manero, G., Verstovšek, S., Wierda, W. G., Thomas, D. A., Faderl, S. H., King, I., O'Brien, S. M., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.013 · Cited by 49
Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome
Horiike, S., Kita‐Sasai, Y., Nakao, M., & Taniwaki, M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000067620 · Cited by 49
The evolving role of lenalidomide in the treatment of hematologic malignancies
Kastritis, E., & Dimopoulos, M. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.497 · Cited by 49
Yue, G., Hao, S., Fadare, O., Baker, S. P., Pozdnyakova, O., Galili, N., Woda, B. A., Raza, A., & Wang, S. A. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.006 · Cited by 49
Martínez‐Ramírez, Á., Urioste, M., Melchor, L., Blesa, D., Valle, L., de Andrés, S. Á., Kok, K., Calasanz, M. J., Cigudosa, J. C., & Benitez, J. J. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20154 · Cited by 49
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
de Swart, L., Reiniers, C., Bagguley, T., van Marrewijk, C., Bowen, D., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Cermak, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.171884 · Cited by 48
Dinardo, C. D., Verma, D., Baran, N., Bhagat, T. D., Skwarska, A., Lodi, A., Saxena, K., Cai, T., Su, X., Guerra, V. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00811-3 · Cited by 48
Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management
Parikh, S. A., & Tefferi, A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23203 · Cited by 48
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
Fenaux, P., & Adès, L. (2009) · Leukemia Research · doi:10.1016/s0145-2126(09)70227-9 · Cited by 48
Self-citationPractical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
Fenaux, P., Bowen, D., Gattermann, N., Hellström‐Lindberg, E., Hofmann, W., Pfeilstöcker, M., Sanz, G. F., & Santini, V. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.021 · Cited by 48
Self-citationBraun, T., de Botton, S., Taksin, A., Park, S., Beyne‐Rauzy, O., Coiteux, V., Sapena, R., Lazareth, A., Leroux, G., Guenda, K., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.02.008 · Cited by 48
Self-citationIron chelation therapy in myelodysplastic syndromes: where do we stand?
Mitchell, M., Gore, S. D., & Zeidan, A. M. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.814456 · Cited by 49
Ye, D., Garcia‐Manero, G., Kantarjian, H. M., Xiao, L., Vadhan‐Raj, S., Fernandez, M. H., Nguyen, M. H., Medeiros, L. J., & Bueso-Ramos, C. (2008) · Journal of Hematopathology · doi:10.1007/s12308-008-0019-3 · Cited by 48
The lower risk MDS patient at risk of rapid progression
Mittelman, M., Oster, H. S., Hoffman, M. A., & Neumann, D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.023 · Cited by 48
Poli, A., Billi, A. M., Mongiorgi, S., Ratti, S., McCubrey, J. A., Suh, P., Cocco, L., & Ramazzotti, G. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25273 · Cited by 51
Zhou, J., Zhang, T., Li, X., Ma, J., Guo, H. Y., Wen, X., Zhang, W., Yang, L., Yang, Y., Lin, J., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13073 · Cited by 48
Rautenberg, C., Pechtel, S., Hildebrandt, B., Betz, B., Dienst, A., Nachtkamp, K., Kondakci, M., Geyh, S., Wieczorek, D., Haas, R. R., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.011 · Cited by 48
Gondek, L. P., Haddad, A. S., O’Keefe, C. L., Tiu, R. V., Włodarski, M. W., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.009 · Cited by 48
Najfeld, V., Cozza, A., Berkofsk-Fessler, W. D., Prchal, J. T., & Scalise, A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.025 · Cited by 48
Mutations of Chk2 in primary hematopoietic neoplasms
Hangaishi, A., Ogawa, S., Qiao, Y., Wang, L., Hosoya, N., Yuji, K., Imai, Y., Takeuchi, K., Miyawaki, S., & Hirai, H. (2002) · Blood · doi:10.1182/blood.v99.8.3075 · Cited by 48
Stasi, R., Brunetti, M., Terzoli, E., & Amadori, S. (2002) · Blood · doi:10.1182/blood.v99.5.1578 · Cited by 48
Čermák, J., Michalova, K., Březinová, J., & Zemanová, Z. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00096-6 · Cited by 48
Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable
Bose, P., Nazha, A., Komrokji, R. S., Patel, K. P., Pierce, S. A., Al‐Ali, N., Sochacki, A. L., Shaver, A. C., Ma, W., Su, X., et al. (2018) · Blood · doi:10.1182/blood-2018-05-848473 · Cited by 47
Chronic relapsing remitting Sweet syndrome – a harbinger of myelodysplastic syndrome
Kulasekararaj, A. G., Kordasti, S. Y., Basu, T. N., Salisbury, J. R., Mufti, G. J., & du Vivier, A. W. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13485 · Cited by 47
Self-citationPrognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome
Kikuchi, S., Kobune, M., Iyama, S., Sato, T., Murase, K., Kawano, Y., Takada, K., Ono, K., Hayashi, T., Miyanishi, K., et al. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1048-3 · Cited by 46
Bally, C., Thépot, S., Quesnel, B., Vey, N., Dreyfus, F., Fadlallah, J., Turlure, P., de Botton, S., Dartigeas, C., Renzis, B. D., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.02.014 · Cited by 47
Self-citationEvers, C., Beier, M., Poelitz, A., Hildebrandt, B., Servan, K., Drechsler, M., Germing, U., Royer, H., & Royer‐Pokora, B. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20498 · Cited by 47
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
Godley, L. A., García, & Jain (2010) · OncoTargets and Therapy · doi:10.2147/ott.s7222 · Cited by 47
Zhou, L., Opalinska, J., Sohal, D. P. S., Yu, Y., Mo, Y., Bhagat, T. D., Abdel-Wahab, O. I., Fazzari, M. J., Figueroa, M. E., Alencar, C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.235028 · Cited by 47
Monosomal karyotype in MDS: explaining the poor prognosis?
Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Grau, J., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2013) · Leukemia · doi:10.1038/leu.2013.187 · Cited by 47
Self-citationControversies surrounding iron chelation therapy for MDS
Leitch, H. A. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.09.003 · Cited by 46
Kuendgen, A., Bug, G., Ottmann, O. G., Haase, D. T., Schanz, J., Hildebrandt, B., Nachtkamp, K., Neukirchen, J., Dienst, A., Haas, R. R., et al. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0031-9 · Cited by 47
The Molecular Pathology of Myelodysplastic Syndrome
Haferlach, T. (2018) · Pathobiology · doi:10.1159/000488712 · Cited by 52
Lin, P., Ren, Y., Yan, X., Luo, Y., Zhang, H., Kesarwani, M., Bu, J., Zhan, D., Zhou, Y., Tang, Y., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.197749 · Cited by 47
Wimazal, F., Sperr, W. R., Kundi, M., Vales, A., Fonatsch, C., Thalhammer-Scherrer, R., Schwarzinger, I., & Valent, P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm595 · Cited by 48
Myeloblast Phenotypic Changes in Myelodysplasia
Pirruccello, S. J., Young, K. H., & Aoun, P. A. (2005) · American Journal of Clinical Pathology · doi:10.1309/j3et-7rxd-1x4b-kdlf · Cited by 47
Molecular cytogenetic aspects of hematological malignancies: Clinical implications
Chen, Z., & Sandberg, A. A. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10689 · Cited by 47
Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes
Alfinito, F., Sica, M., Luciano, L., Pepa, R. D., Palladino, C., Ferrara, I., Giani, U., Ruggiero, G., & Terrazzano, G. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07921.x · Cited by 48
Nguyen, P. L. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.04.008 · Cited by 46
Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia
Courville, E. L., Wu, Y., Kourda, J., Roth, C. G., Brockmann, J., Muzikansky, A., Fathi, A. T., de Leval, L., Orazi, A., & Hasserjian, R. P. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.218 · Cited by 46
Raza, A., Galili, N., Smith, S. E., Godwin, J. E., Boccia, R. V., Myint, H., Mahadevan, D., Mulford, D. A., Rarick, M. U., Brown, G. L., et al. (2011) · Cancer · doi:10.1002/cncr.26469 · Cited by 46
Kelaïdi, C., Beyne‐Rauzy, O., Braun, T., Sapena, R., Cougoul, P., Adès, L., Pillard, F., Lambert, C., Charniot, J.-C., Guerci‐Bresler, A., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1686-4 · Cited by 46
Self-citationHeesch, S., Schlee, C., Neumann, M., Stroux, A., Kühnl, A., Schwartz, S., Haferlach, T., Goekbuget, N., Hoelzer, D. T., THIEL, E., et al. (2010) · Leukemia · doi:10.1038/leu.2010.130 · Cited by 46
Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Hahn, C. N., Venugopal, P., Scott, H. S., & Hiwase, D. (2014) · Immunological Reviews · doi:10.1111/imr.12241 · Cited by 46
Lim, Z. Y., Ingram, W. A., Brand, R., Ho, A. Y. L., Kenyon, M., Devereux, S., Marsh, J. C. W., Mufti, G. J., & Pagliuca, A. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.236 · Cited by 46
Self-citationAu, B. K. C., Gooley, T. A., Armand, P. A., Fang, M., Madtes, D. K., Sorror, M. L., Boeckh, M. J., Gibson, C. J., Deeg, H. J., Storb, R. F., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.01.011 · Cited by 46
Lyons, R. M., Marek, B. J., Paley, C. S., Esposito, J., Garbo, L. E., DiBella, N. J., & Garcia‐Manero, G. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.11.004 · Cited by 46
Efficace, F., Gaïdano, G., Sprangers, M. A. G., Cottone, F., Breccia, M., Voso, M. T., Caocci, G., Stauder, R., Tucci, A. A. D., Sanpaolo, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt557 · Cited by 46
Hematopoietic Stem Cell Transplantation for MDS
Bartenstein, M., & Deeg, H. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.003 · Cited by 46
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Cogle, C. R., Scott, B. L., Boyd, T. E., & Garcia‐Manero, G. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0165 · Cited by 46
Robin, M., Porcher, R., Zinke-Cerwenka, W., van Biezen, A., Volin, L., Mufti, G. J., Craddock, C., Finke, J., Richard, C., Passweg, J. R., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.266 · Cited by 46
Self-citationTransplantation for myelodysplastic syndromes: who, when, and which conditioning regimens
Saber, W., & Horowitz, M. M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.478 · Cited by 46
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
Piérola, A. A., Bravo, G. M., Takahashi, K., Jabbour, E. J., Kadia, T. M., Ravandi, F., Cortes, J. E., Estrov, Z. E., Borthakur, G. M., Pemmaraju, N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24735 · Cited by 46
Mangaonkar, A. A., Swoboda, D. M., Coltro, G., Lasho, T. L., Novotny, P. J., Pophali, P. A., Carr, R. M., Binder, M., Finke, C. M., Gangat, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0574-x · Cited by 46
Germing, U., Olíva, E. N., Hiwase, D., & Almeida, A. M. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000314 · Cited by 48
Giannouli, S., Tzoanopoulos, D., Ritis, K., Kartalis, G., Moutsopoulos, H. M., & Voulgarelis, M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.012948 · Cited by 46
Bourgeois, E., Caulier, M., Rosé, C., Dupriez, B., Bauters, F., & Fenaux, P. (2001) · Leukemia · doi:10.1038/sj.leu.2402129 · Cited by 46
Self-citationBehçet Disease Associated With Myelodysplastic Syndrome
Lin, Y., Liang, T., Chang, H.-N., Js, L., & Lin, H.-Y. (2008) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181776bde · Cited by 46
Novel therapies for myelodysplastic syndromes
Faderl, S. H., & Kantarjian, H. M. (2004) · Cancer · doi:10.1002/cncr.20381 · Cited by 46
Oosterveld, M., Suciu, S., Verhoef, G. E. G., Labar, B., Belhabri, A., Aul, C., Selleslag, D., Ferrant, A., Wijermans, P., Mandelli, F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402897 · Cited by 46
Self-citationRigolin, G. M., Howard‐Reeves, J., Buggins, A. G. S., Sneddon, C., Castoldi, G., Hirst, W. J. R., & Mufti, G. J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01781.x · Cited by 47
Self-citationBench, A. J., Cross, N. C. P., Huntly, B. J. P., Nacheva, E. P., & Green, A. R. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0153 · Cited by 46
Mufti, G. J., List, A. F., Gore, S. D., & Ho, A. Y. L. (2003) · Hematology · doi:10.1182/asheducation-2003.1.176 · Cited by 46
Self-citationTelomere Dynamics in Myelodysplastic Syndromes and Acute Leukemic Transformation
Ohyashiki, K., Iwama, H., Yahata, N., Tauchi, T., Kawakubo, K., Shimamoto, T., & Ohyashiki, J. H. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109064585 · Cited by 46
Self-citationApoptosis and its significance in MDS: controversies revisited
Yoshida, Y., & Mufti, G. J. (1999) · Leukemia Research · doi:10.1016/s0145-2126(99)00094-6 · Cited by 46
Self-citationRefractory anemia with ring sideroblasts and RARS with thrombocytosis
Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24038 · Cited by 45
Zeidan, A. M., Hendrick, F. B., Friedmann, E., Baer, M. R., Gore, S. D., Sasané, M., Paley, C. S., & Davidoff, A. J. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.20 · Cited by 44
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
Kulasekararaj, A. G., Mohamedali, A. M., & Mufti, G. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12435 · Cited by 47
Self-citationRobin, M., Porcher, R., Adès, L., Boissel, N., Raffoux, E., Xhaard, A., Larghero, J., Gardin, C., Himberlin, C., Delmer, A. J., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.50 · Cited by 45
Self-citationBoehm, A., Sperr, W. R., Leitner, G. C., Worel, N., Oehler, L., Jaeger, E., Mitterbauer, M., Haas, O. A., Valent, P., Kalhs, P., et al. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02041.x · Cited by 45
Predicting survival of patients with hypocellular myelodysplastic syndrome
Tong, W., Quintás‐Cardama, A., Kadia, T. M., Borthakur, G. M., Jabbour, E. J., Ravandi, F., Faderl, S. H., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2012) · Cancer · doi:10.1002/cncr.27420 · Cited by 45
Robin, M., Sanz, G. F., Ionescu, I., Rio, B., Sîrvent, A., Renaud, M., Carreras, E., Milpied, N. J., Mohty, M., Beguin, Y. P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.219 · Cited by 45
Self-citationFISH analysis in addition to G-band karyotyping: Utility in evaluation of myelodysplastic syndromes?
Yang, W., Stotler, B. A., Sevilla, D. W., Emmons, F. N., Murty, V. V. V. S., Alobeid, B., & Bhagat, G. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.09.013 · Cited by 45
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 45
Berggren, D. M., Folkvaljon, Y., Engvall, M., Sundberg, J., Lambe, M. P., Antunović, P., Garelius, H. G., Lorenz, F., Nilsson, L., Rasmussen, B. E. H., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15243 · Cited by 47
Patnaik, M. M., & Tefferi, A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25397 · Cited by 46
Greenberg, P. L., Cosler, L. E., Ferro, S. A., & Lyman, G. H. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0072 · Cited by 44
Self-citationArsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovšek, S., Giles, F. J., Quintás‐Cardama, A., Perez, N., Ravandi‐Kashani, F., Beran, M., Freireich, E. J., & Kantarjian, H. M. (2006) · Hematological Oncology · doi:10.1002/hon.787 · Cited by 45
Porta, M. G. D., Malcovati, L., Rigolin, G. M., Rosti, V., Bonetti, E., Travaglino, E., Boveri, E., Gallì, A., Boggi, S., Ciccone, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405069 · Cited by 46
Metadata
- Authors
- Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., & Bennett, J.
- Affiliations
- Tokyo Medical University (JP)
- From the Hematology Divisions of Stanford University Medical Center, Stanford, CA; the Rochester Medical Center, Rochester, NY; the University of Chicago, Chicago, IL; Centre Hospitalier Universitaire, Lille, France; Hospital La Fe, Valencia, Spain; Hospital Vall d'Hebron, Barcelona, Spain; the Royal Bournemouth Hospital, Bournemouth, UK; the Tokyo Medical College, Tokyo, Japan; the Heinrich Heine University, Dusseldorf, Germany; and the King's College Hospital, London, UK.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-03-15
- Volume
- 89
- Issue
- 6
- Pages
- 2079-2088
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W187238933
- Cited by
- 4,427
- References
- 33
- Citations by year
- 2026: 45 · 2025: 69 · 2024: 93 · 2023: 124 · 2022: 131 · 2021: 155 · 2020: 167 · 2019: 144 · 2018: 174 · 2017: 226 · 2016: 183 · 2015: 205 · 2014: 232 · 2013: 253 · 2012: 256
- FWCI
- 36.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- myelodysplastic syndrome, prognostic score, International Prognostic Scoring System, risk stratification, bone marrow cytogenetics, acute myeloid leukemia transformation, bone marrow blasts, cytopenia, survival, del(5q), del(20q)
- MeSH terms
- Acute Disease, Adolescent, Adult, Age Factors, Aged, Bone Marrow, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Sex Factors, Multivariate Analysis, Survival Analysis, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
